CRIS Current Research Information System

MARTINELLI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.128
EU - Europa 25.760
AS - Asia 14.865
AF - Africa 1.683
SA - Sud America 114
Continente sconosciuto - Info sul continente non disponibili 70
OC - Oceania 42
Totale 75.662
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.947
GB - Regno Unito 7.878
CN - Cina 5.211
VN - Vietnam 4.040
SE - Svezia 3.995
IT - Italia 3.838
DE - Germania 3.150
SG - Singapore 3.076
RU - Federazione Russa 1.478
IN - India 1.437
IE - Irlanda 1.014
UA - Ucraina 997
FR - Francia 974
ZA - Sudafrica 576
TG - Togo 553
EE - Estonia 548
CH - Svizzera 401
FI - Finlandia 331
BG - Bulgaria 296
CI - Costa d'Avorio 270
JO - Giordania 256
JP - Giappone 210
NG - Nigeria 189
GR - Grecia 184
BE - Belgio 183
CA - Canada 169
IR - Iran 147
NL - Olanda 141
AT - Austria 91
HK - Hong Kong 79
SC - Seychelles 77
ID - Indonesia 76
TR - Turchia 67
EU - Europa 65
BR - Brasile 61
KR - Corea 52
HR - Croazia 45
UZ - Uzbekistan 44
LB - Libano 41
ES - Italia 40
PL - Polonia 37
AU - Australia 33
CL - Cile 29
PH - Filippine 26
CZ - Repubblica Ceca 24
RO - Romania 23
LT - Lituania 18
MY - Malesia 16
TW - Taiwan 15
PT - Portogallo 13
SA - Arabia Saudita 11
EG - Egitto 10
RS - Serbia 10
BD - Bangladesh 9
IL - Israele 9
NO - Norvegia 9
NZ - Nuova Zelanda 9
MX - Messico 8
PE - Perù 8
AE - Emirati Arabi Uniti 6
AR - Argentina 6
DK - Danimarca 6
MK - Macedonia 6
SK - Slovacchia (Repubblica Slovacca) 6
A2 - ???statistics.table.value.countryCode.A2??? 5
KZ - Kazakistan 5
LU - Lussemburgo 5
PK - Pakistan 5
EC - Ecuador 4
HU - Ungheria 4
KG - Kirghizistan 4
QA - Qatar 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
IQ - Iraq 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
MA - Marocco 3
AM - Armenia 2
AZ - Azerbaigian 2
CO - Colombia 2
LI - Liechtenstein 2
MD - Moldavia 2
PA - Panama 2
TM - Turkmenistan 2
BO - Bolivia 1
BS - Bahamas 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
KE - Kenya 1
LK - Sri Lanka 1
MC - Monaco 1
ML - Mali 1
PY - Paraguay 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
Totale 75.659
Salva come PNG Salva come JPEG
Città #
Southend 7.305
Fairfield 4.103
Chandler 3.290
Singapore 2.585
Dong Ket 2.581
Ashburn 2.476
Woodbridge 2.048
Houston 2.033
Wilmington 1.888
Seattle 1.810
Ann Arbor 1.622
Princeton 1.431
Cambridge 1.413
Santa Clara 1.191
Dublin 1.008
Boardman 890
Nanjing 662
Westminster 651
Bologna 650
Padova 623
Lomé 553
Beijing 549
Jacksonville 499
Berlin 352
Bern 336
Jinan 336
Saint Petersburg 321
Helsinki 319
Shenyang 315
New York 310
Medford 289
Sofia 287
Abidjan 270
Amman 256
Milan 252
Hebei 246
San Diego 236
Turin 234
Changsha 219
Nanchang 218
Bremen 201
Abeokuta 188
Redmond 178
Brussels 176
Tianjin 158
Florence 149
Jiaxing 148
Tokyo 147
Falls Church 138
Redwood City 138
Guangzhou 130
Mülheim 125
Zhengzhou 124
Shanghai 116
Norwalk 110
Hangzhou 98
Los Angeles 97
Rome 96
Haikou 95
Toronto 94
Falkenstein 88
Ningbo 88
Taizhou 87
Dearborn 78
Jakarta 72
Mountain View 72
Mahé 71
Phoenix 67
Yubileyny 67
Des Moines 66
Hong Kong 61
Bühl 60
Olalla 60
London 58
Taiyuan 58
Frankfurt am Main 56
Vienna 52
Lanzhou 51
Paris 51
Hyderabad 50
Kunming 49
Verona 48
Fuzhou 46
Istanbul 46
Nuremberg 45
Forlì 44
Wuhan 41
Andover 37
Amsterdam 36
Athens 36
Xi'an 36
Chengdu 35
Leawood 34
Washington 34
Fremont 31
Zanjan 31
Harbin 29
Shenzhen 29
São Paulo 27
Moscow 26
Totale 51.416
Salva come PNG Salva come JPEG
Nome #
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 589
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 336
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 289
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 279
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 256
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 241
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 239
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 235
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 230
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 228
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 226
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 222
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 221
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 221
5′UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia 219
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 214
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 214
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 208
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 207
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 206
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 202
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 201
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 201
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 201
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 200
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 196
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 194
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 193
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 192
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 190
Cauliflower Mosaic Virus TAV, a Plant Virus Protein That Functions like Ribonuclease H1 and is Cytotoxic to Glioma Cells 189
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 183
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 183
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 181
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 179
A case report of acute myeloid leukemia and neurofibromatosis 1 179
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 179
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 177
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 177
Advances in the treatment for haematological malignancies. 176
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 176
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 175
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 174
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 174
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 171
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 171
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 170
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 170
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 170
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 169
Assessment of the interlaboratory variability and robustness of JAK2V617Fmutation assays: A study involving a consortium of 19 Italian laboratories 169
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 168
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 167
14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia 167
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 167
Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Coronary Artery Disease and in Centenarians. Further Clues Linking Chip with Cardiovascular Risk 167
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 166
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 165
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 165
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 164
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 164
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 164
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 164
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 163
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 163
Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia 162
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 162
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 162
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 161
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 161
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 160
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 160
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 159
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 159
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model 158
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 157
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 157
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 157
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 156
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 156
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 155
CHK2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571 155
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 155
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 153
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 153
Accuracy of Mobile Applications versus Wearable Devices in Long-Term Step Measurements 153
Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. 152
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 152
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 151
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 151
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes 151
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 151
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 150
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 149
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 149
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 149
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 148
Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: Results from a phase II, single-arm, multicenter study 148
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 147
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 147
Totale 18.462
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.754
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207.840 0 0 0 0 0 0 0 2.145 2.529 1.164 869 1.133
2020/202110.786 1.826 619 199 306 271 451 243 604 999 489 521 4.258
2021/202213.288 1.535 364 875 1.149 1.272 869 288 883 603 982 2.280 2.188
2022/202314.358 1.686 2.270 759 1.884 945 1.088 505 775 2.257 322 1.167 700
2023/20244.044 222 612 227 377 296 884 269 302 173 249 216 217
2024/20259.753 547 2.291 1.245 1.007 2.117 758 1.293 495 0 0 0 0
Totale 77.525